医药板块跑赢大市中生(01177.HK)复星医药(02196.HK)弹4.4%-6%
恒指及国指扭五连跌反弹，半日收28,205及10,701，回升0.3%及0.5%。医药板块今早跑赢大市，尤其是旗下用於治疗机能减退女性性慾障碍注射液获批及拟最多2.5亿人民币收购葛兰素史克制药(苏州)的复星医药(02196.HK)扭三连跌，最高见24.9元，半日收24.65元，回升6%；获里昂升价至15%至10.56元以反映旗下重磅药品安罗替尼获注册获批对公司收入贡献的中生制药(01177.HK)连吐两天守稳10天线，半日股价回升4.4%报8.81元。同为蓝筹石药(01093.HK)扭四连跌，半日回升3.6%报12.64元，股价挑战10天线(12.69元)。
金斯瑞生物(01548.HK)升破20天及10天线(19.28-19.55元)，最高见19.86元，半日收19.64元，续升3.5%。三生制药(01530.HK)回升2.9%，报14.12元，股价重越10天及100天线(13.9元)。华润医药(03320.HK)回升3.9%报8.83元，股价重越10天线(8.81元)。威高股份(1066.HK)回落守稳牛熊线，今早股价一举重越4条移动平均线(7.1-7.18元)，最高见7.35元，半日收7.26元，回升3.7%。石四药(02005.HK)曾越100天及250天线(6.95-6.97元)，最高见6.98元，半日收6.94元，回升3%。丽珠医药(01513.HK)半日回升3.2%报19.1元，股价重越50天及10天线(18.87元)。上海医药(02607.HK)由52周低位回升2%报15.16元，挑战10天线(15.23元)。绿叶制药(02186.HK)重越10天线(5.78元)，半日收5.8元，回升2.7%。爱康医疗(01789.HK)回升3.8%报4.38元，创逾三个月高，但暂受制牛熊线(4.53元)之下。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
